A Nomogram to Preoperatively Predict 1-year Disease-Specific Survival in Resected Pancreatic Cancer Following Neoadjuvant Chemoradiation Therapy by 강창무 et al.
A nomogram to preoperatively predict 1-year disease-specific
survival in resected pancreatic cancer following neoadjuvant
chemoradiation therapy
Ho  Kyoung  Hwang1,2*,  Keita  Wada3*,  Ha  Yan  Kim4,  Yuichi  Nagakawa5,  Yosuke  Hijikata5,
Yota  Kawasaki6,  Yoshiharu  Nakamura7,  Lip  Seng  Lee8,  Dong  Sup  Yoon1,2,  Woo  Jung  Lee1,2,
Chang Moo Kang1,2
1Division of HBP Surgery, Department of Surgery, Yonsei University College of Medicine, Seoul 03722, Korea; 2Pancreatobiliary Cancer Clinic,
Yonsei Cancer Center, Severance Hospital, Seoul 03722, Korea; 3Department of Surgery, Teikyo University School of Medicine, Tokyo 173-8605,
Japan; 4Biostatistician, Biostatistics Collaboration Unit, Department of Biomedical Systems Informatics, Yonsei University College of Medicine,
Seoul 03722, Korea; 5Department of Gastrointestinal and Pediatric Surgery, Tokyo Medical University, Tokyo 160-8402, Japan; 6Department of
Digestive Surgery, Breast, and Thyroid Surgery, Graduate School of Medical Sciences, Kagoshima University, Kagoshima 890-0065, Japan;
7Department of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Nippon Medical School, Tokyo 890-0065, Japan; 8Department of General
Surgery, Changi General Hospital, Singapore 529889, Singapore
*These authors contributed equally to this work.
Correspondence to: Chang Moo Kang, M.D., Ph.D. Division of HBP Surgery, Department of Surgery, Yonsei University College of Medicine, 50-1
Yonsei-ro, Seodaemun-gu, Seoul 120-752, Korea. Email: cmkang@yuhs.ac.
Abstract
Objective: This study aimed to develop a nomogram to predict the 1-year survival of patients with pancreatic
cancer who underwent pancreatectomy following neoadjuvant treatment with preoperatively detectable clinical
parameters. Extended pancreatectomy is necessary to achieve complete tumor removal in borderline resectable and
locally advanced pancreatic cancer. However, it increases postoperative morbidity and mortality rates, and should
be balanced with potential benefit of long-term survival.
Methods: The medical records of patients who underwent pancreatectomy following neoadjuvant treatment from
January 2005 to December 2016 at Severance Hospital  were retrospectively reviewed. Medical records were
collected from five international institutions from Japan and Singapore for external validation.
Results: A total of 113 patients were enrolled. The nomogram for predicting 1-year disease-specific survival was
created based on 5 clinically detectable preoperative parameters as follows: age (year), symptom (no/yes), tumor size
at  initial  diagnostic  stage (cm),  preoperative  serum carbohydrate  antigen (CA) 19-9 level  after  neoadjuvant
treatment (<34/≥34 U/mL), and planned surgery [pancreaticoduodenectomy (PD) (pylorus-preserving PD)/distal
pancreatectomy (DP)/total pancreatectomy]. Model performance was assessed for discrimination and calibration.
The  calibration  plot  showed  good  agreement  between  actual  and  predicted  survival  probabilities;  the  the
Greenwood-Nam-D’Agostino (GND) goodness-of-fit test showed that the model was well calibrated (χ2=8.24,
P=0.5099). A total of 84 patients were used for external validation. When correlating actual disease-specific survival
and calculated 1-year disease-specific survival, there were significance differences according to the calculated
probability of 1-year survival among the three groups (P=0.044).
Conclusions: The developed nomogram had quite acceptable accuracy and clinical feasibility in the decision-
making process for the management of pancreatic cancer.
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Introduction
Pancreatic cancer is among the most fatal cancers of the
gastrointestinal tract. The overall 5-year survival rate of
pancreatic cancer is only approximately 6%, and it is the
fourth leading cause of cancer-related deaths in the United
States  (1)  as  well  as  in  Korea  (2).  Although  surgical
resection with clear safe margin is the only modality for
curative treatment, only 20% of patients are eligible for
surgical resection at the time of initial diagnosis because
majority of patients are often diagnosed in the late stage
and thus  have poor general  condition.  Moreover,  more
than 50% of patients who undergo curative surgery develop
recurrence within 1 year, and the 5-year survival rate of
resected pancreatic cancer is less than 20% (1,3,4).
According  to  the  National  Comprehensive  Cancer
Network  (NCCN)  guideline  (5),  pancreatic  cancers
requiring neoadjuvant treatment are those that involve the
major  vascular  structures  and  adjacent  organs.  When
margin-negative  resection  is  considered  as  the  most
effective treatment (6), extended pancreatectomy including
combined  major  vascular  resection  and  adjacent  organ
resection  may  be  necessary  to  achieve  complete  tumor
removal  in  borderline  and  locally  advanced  pancreatic
cancers. However, extended pancreatic resections following
combined preoperative  chemotherapy and radiotherapy
before  surgery are  known to increase  the rates  of  post-
operative morbidity and mortality.
Several randomized control studies (7-10) that compared
oncologic outcomes and short-term perioperative outcomes
between  extended  pancreatectomy  and  standard  pan-
createctomy  showed  that  extended  pancreatectomy  is
associated with severe complications without improving
oncologic  outcomes.  Bhayani  et  al.  (11)  analyzed  273
extended  pancreatoduodenectomies  from  the  National
Surgical  Quality  Improvement  Project  database  and
reported  a  threefold  increase  in  major  perioperative
morbidity  and  mortality  rates  even  after  adjusting  for
comorbidity in such surgical strategy. Hartwig et al. (12)
also  recently  assessed  the  outcome  of  extended
pancreatectomy  for  borderline  resectable  and  locally
advanced  pancreatic  cancer  and  showed  that  extended
resections  were  associated  with  increased  perioperative
morbidity and mortality.
Surgeons need to consider many clinical and practical
factors when deciding the need for pancreatectomy, such as
potential oncologic benefit of surgical approach, patients’
existing co-morbidity, expected life span of the patients,
quality  of  life  after  surgery,  potential  postoperative
complications, and surgery-related mortality. If possible, it
was  a  good  strategy  to  avoid  unnecessary  surgery  in
patients without surgical benefits.
In  this  study,  we  aimed  to  develop  a  nomogram  to
predict  the  1-year  survival  of  patients  with  pancreatic
cancer  who  underwent  pancreatectomy  following
neoadjuvant  treatment  with  preoperatively  detectable
clinical  parameters  to  ultimately  provide  a  basis  for
decision-making  for  the  appropriate  management  of
pancreatic cancer following neoadjuvant treatment.
Materials and methods
Study population
This  study  protocol  was  approved  by  the  Institutional
Review Board of Yonsei University College of Medicine
(Approval number: 4-2018-0374). The medical records of
the  patients  who  underwent  pancreatectomy  following
neoadjuvant treatment from January 2005 to December
2016 were retrospectively reviewed. Neoadjuvant treatment
was routinely performed for the patients with borderline
resectable or locally advanced pancreatic cancer. Among
patients in the resectable stage, neoadjuvant treatment was
performed  preoperatively,  even  if  there  was  no  major
vascular  involvement,  but  the  tumor size  was  large and
there was invasion to the surrounding organs.
In  this  study,  we  included  patients  who  underwent
neoadjuvant  treatment  before  surgery  and were  able  to
perform curative resection in pancreatic cancer. Patients
who did not attempt pancreatic resection due to distant
metastasis found during surgery and patients who did not
undergo curative resection due to severe major vascular
invasion were excluded.
Data collection
Data on clinicopathologic variables, such as sex, age, serum
carbohydrate antigen (CA) 19-9, tumor location, operation
type, tumor size, tumor grade (differentiation), pathologic
tumor  (pT)  stage,  presence  of  lymph  node  metastasis,
lymph node ratio (i.e., total number of metastatic lymph
nodes  divided  by  the  total  number  of  retrieved  lymph
node), microscopic perineural invasion and lymphovascular
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invasion,  and  disease-specific  survival  were  collected.
Surgeons followed up all the patients, usually every 3−4
months and the follow-up continued until recurrence or
death was confirmed.
External validation
External  validation  to  test  the  accuracy  of  developed
nomogram to predict 1-year disease-specific survival was
conducted by reviewing the medical records of the patients
who  underwent  pancreatectomy following  neoadjuvant
treatment  for  pancreatic  cancer  from five  international
institutions from Japan and Singapore.
Statistical analysis
When developing the  prediction model,  preoperatively
available  clinical  parameters  were  included  in  the  final
model that achieved statistical significance in the univariate
Cox model and were also considered clinically important.
Based  on  the  results  of  the  multivariate  Cox  model,  a
nomogram  was  created  by  using  the  package  rms  in  R
software  (Version  3.1.3;  R  Foundation  for  Statistical
Computing, Vienna, Austria) (http://www.r-project.org/).
Serum CA19-9 levels were divided into two based on a cut-
off of 34 U/mL, which was based on the proposal of Contal
and O’Quigley (13) as determined via log-rank test.
To quantify  the  discriminative  capability  of  the  final
model, Harrell’s C-index was measured. Calibration was
evaluated  via  a  calibration  plot,  which  is  a  graphic
representation of the relationship between the observed
and  predicted  survival,  and  the  Greenwood-Nam-D’
Agostino  (GND)  goodness-of-fit  test  (14).  Internal
validation  was  performed  using  1,000  bootstrapped
resamples  and  also  generated  the  calibration  plot.  To
further  assess  the calibration,  we plotted Kaplan-Meier
curves  over  the  risk-stratified  groups  by  the  predicted
probability  by  the  nomogram.  Finally,  we  tested  the
performance of the nomogram in the external validation
cohort. The formula derived in the development cohort
was  applied  to  all  patients  in  the  validation cohort.  To
further validate the nomogram, patients were categorized
into three risk groups according to the nomogram-based
calculated 1-year disease-specific survival probability, and
survival was compared between the three groups using log-
rank test. Continuous variables were described as , and
categorical  variables were described as a frequency (%).
Student’s t-test, Chi-square test, or Fisher’s exact test were
performed  as  appropriate.  Statistical  analyses  were
performed using SAS software (Version 9.4, SAS Institute,




During  the  study  period,  113  patients  underwent
pancreatectomy following  neoadjuvant  chemoradiation
therapy. Of these, 64 were men and 49 were women. The
mean age was 51.5±9.4 years old.  A total  of  42 (37.2%)
patients were asymptomatic. In terms of resectability, 46
(40.7%)  patients  had  resectable  pancreatic  cancer,  46
(40.7%) had borderline resectable pancreatic cancer, and
21 (18.6%) had locally advanced pancreatic cancer. The
most common location of the tumor was the pancreatic
head (86/113, 76.1%), followed by the pancreatic body/tail
(27/113,  23.9%).  Pylorus-preserving pancreaticoduode-
nectomy (PPPD) was performed in 83 (73.5%) patients,
distal pancreatosplenectomy (DPS) in 27 (23.9%) patients;
and  total  pancreatectomy  (TP)  in  3  (2.7%)  patients.
Combined venous vascular  resection including superior
mesenteric vein (SMV)-splenic vein (SV)-portal vein (PV)
confluence  was  performed in  40  (35.4%) patients.  The
maximum diameter of the resected pancreatic cancer was
2.1±1.5 cm. Lymphovascular and perineural invasion were
observed  in  10  (8.8%)  and  50  (44.2%)  patients,
respectively.  Lymph  node  metastasis  was  found  in  36
(31.9%) patients.  The median disease-free  survival  and
disease-specific survival was 11.0 [95% confidence interval
(95% CI): 8.8−13.2] months and 29.0 (95% CI: 1.6−38.4)
months, respectively. Twenty-seven (23.9%) patients were
found  to  have  cancer-related  mortality  within  1  year
postoperatively.
Preoperative  factors  to  predict  1-year  disease-specific
survival
In univariate analysis, age (P=0.0165), serum CA 19-9 (after
neo-Tx) following neoadjuvant treatment (P=0.0023), and
preoperative  image-based  tumor  size  (P=0.0469)  were
statistically significant preoperative parameters to predict
less than 1-year disease-specific survival in patients with
pancreatic  cancer  who  underwent  pancreatectomy
following neoadjuvant treatment. Subsequent multivariate
analysis showed that age [hazard ratio (HR)=1.062, 95%
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CI: 1.008−1.118, P=0.024] and CA 19-9 ≥34 U/mL (after
neo-Tx) following neoadjuvant treatment (HR=2.863, 95%
CI: 1.123−7.300, P=0.0276) were independent prognostic
factors to predict less than 1-year disease-specific survival
(Table 1).
Developing nomogram to predict 1-year disease-specific
survival and model performance
Of the 113 patients, the variables of “preoperative serum
CA 19-9 after neoadjuvant treatment” were missing in 9
patients, we excluded this data and 104 patients were finally
analyzed. Based on the complete survival-specific data and
preoperatively available parameters of the 104 patients, the
nomogram to predict 1-year disease-specific survival of the
patients  who  underwent  pancreatectomy  following
neoadjuvant treatment for pancreatic cancer was created
(Figure 1). The nomogram was created based on 5 clinically
detectable preoperative parameters: age (year), symptom
(no/yes)  on initial  diagnosis,  image-based tumor size at
initial diagnostic stage (cm), preoperative serum CA 19-9
(after neo-Tx) (<34/≥34 U/mL), and planned surgery [PD
(PPPD)/DPS/TP]. The model performance was quantified
via Harrells’ c-statistics, which was 0.736 [standard error
(SE) =0.064].
Table 1 Univariate and multivariate analyses showing association between preoperative clinical parameters and 1-year disease-specific
survival
Variables
Univariate analysis Multivariate analysis
HR 95% CI P HR 95% CI P
Age (year) 1.058 1.101−1.108 0.0165 1.062 1.008−1.118 0.0241
Sex, male 0.858 0.398−1.848 0.6947
BMI (kg/m2) 0.861 0.740−1.002 0.0538
Symptom, yes 1.954 0.826−4.625 0.1273 2.019 0.692−5.891 0.1986
Weight loss, yes 1.206 0.487−2.989 0.6855
Jaundice, yes 0.598 0.268−1.331 0.2076
Abdominal pain, yes 1.921 0.903−4.087 0.0903
Dyspepsia, yes 1.414 0.571−3.504 0.4541
ASA score
　2 vs. 1 0.987 0.406−2.398 0.9761
　3 vs.1 0.703 0.182−2.721 0.6103
　4 vs. 1 NA NA NA
CA19-9 (initial diagnosis) 1 1.000−1.000 0.2564
CA19-9 (after neo-Tx) 1.001 1.000−1.001 0.0023
CA19-9 (after neo-Tx) (≥34) (U/mL) 2.302 0.966−5.489 0.0612 2.863 1.123−7.300 0.0276
Tumor size on imaging (cm) 1.450 1.005−2.093 0.0469 1.243 0.800−1.931 0.3336
Smoking, yes 1.060 0.485−2.314 0.8841
Tumor location 1.679 0.754−3.739 0.2044
Initial resectability
　2 vs. 1 0.423 0.173−1.038 0.0605
　3 vs. 1 0.711 0.258−1.957 0.5092
Predicted surgery
　PD/PPPD reference
　DPS 1.751 0.780−3.928 0.1745 1.922 0.697−5.285 0.2068
　TP 3.726   0.493−28.134 0.2022 1.522   0.179−12.904 0.7003
BMI,  body  mass  index;  ASA,  American  Society  of  Anesthesiologist;  NA,  not  available;  CA,  carbohydrate  antigen;  neo-Tx,
neoadjuvant treatment; Resectability 1, resectable; Resectability 2, borderline resectable; Resectability 3, locally advanced; PD,
pancreaticoduodenectomy; PPPD, pylorus-preserving PD; TP, total pancreatectomy; HR, hazard ratio; 95% CI, 95% confidence
interval.
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Validation of nomogram
Model performance for discrimination and calibration was
assessed. Discrimination was validated using the bootstrap
validation  with  1,000  resamples.  The  calibration  plot
(Figure  2)  showed  good  agreement  between  actual  and
predicted survival probabilities, and the GND goodness-of-
fit test showed that the model was well calibrated (χ2=8.24,
P=0.5099). To further assess the discriminating capability
of the nomogram, according to nomogram-based estimated
1-year disease-specific survival probability, patients were
categorized into three risk groups as follows: the low-risk
group  comprised  patients  with  a  nomogram-based
calculated 1-year disease-specific  survival  probability of
<33.3%; the intermediate-risk group, 33.3%−66.6%; and
the  high-risk  group,  >66.6%.  Statistically  significant
differences  in  the  survival  rates  were  found among the
three groups (P<0.001, Figure 3).
External validation to assess nomogram performance in
predicting 1-year disease-specific survival
Institutional data of the patients who underwent resection
following neoadjuvant treatment were obtained from five
international hospitals. A total of 84 patients were used for
 
Figure 1 Nomogram to predict 1-year disease-specific survival of patients with pancreatic cancer who underwent resection following
neoadjuvant treatment. Only preoperative clinical parameters, such as, age, symptom, image-based tumor size at diagnosis, preoperative
serum CA 19-9 after neoadjuvant treatment, and planned surgery, were considered in developing a nomogram. CA, carbohydrate antigen;
PP,  pancreaticoduodenectomy;  PPPD,  pylorus-preserving  pancreaticoduodenectomy;  TP,  total  pancreatectomy;  DPS,  distal
pancreatosplenectomy; DSS, disease-specific survival.
 
Figure 2 Calibration plot comparing predicted and actual 1-year
survival. The “apparent” curve was calculated directly from the
development dataset. The “bias-corrected” curve was adjusted via
bootstrap with 1,000 resamples.
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external validation to assess the nomogram performance.
Patients’ age (61.4±9.6 vs. 66.9±9.7, P=0.0001) and serum
CA 19-9 (after neo-Tx) (≥34 U/mL) following neoadjuvant
treatment  [48  (46.2%)  vs.  64  (74.4%),  P<0.0001]  were
statistically significant between the study cohort and the
validation cohort (Table 2).  Moreover, when correlating
actual  disease-specific  survival  and  calculated  1-year
disease-specific survival, there was statistically significant
differences according to the calculated probability of 1-year
survival among the three groups (P=0.044, Figure 4).
Discussion
Pancreatic cancer is  the fourth leading cause of cancer-
associated  mortality,  with  approximately  43,090  deaths
recorded in 2017 in the United States (15). The median
survival is 26 months, and the 5-year survival rate is 30%
(6). Margin-negative pancreatectomy followed by adjuvant
chemotherapy  is  the  standard  treatment  modality  for
resectable pancreatic cancer. However, only 15%−20% of
the  patients  are  eligible  for  resection  at  the  time  of
diagnosis.  In addition, patients who underwent margin-
positive  pancreatectomy  show  poor  survival  outcomes
similar  to  those with locally  advanced and unresectable
pancreatic cancer (6). Therefore, neoadjuvant treatment
has  been  utilized  for  borderline  resectable  and  locally
advanced  (unresectable)  pancreatic  cancer  to  improve
eligibility for surgical resection, with the ultimate aim to
optimize the treatment outcomes and minimize the risk of
treatment-related morbidity.
Studies  (16,17)  have  shown  the  importance  of  neo-
adjuvant treatment in pancreatic cancer. A recent meta-
analysis (18) of studies reporting median overall survival by
intention to treat in patients with resectable or borderline
resectable  pancreatic  cancer  treated  with  or  without
neoadjuvant treatment showed that neoadjuvant treatment
appears to improve overall survival (18.8 months vs. 14.8
months) despite lower overall  resection rates (66.0% vs.




Study cohort (N=104) Validation cohort (N=86)
Age (year) 61.4±9.6 66.9±9.7   0.0001
Symptom, yes 66 (63.5) 58 (67.4)   0.5663
Preoperative serum CA19-9 (after neo-Tx) (≥34) (U/mL) 48 (46.2) 64 (74.4) <0.0001
Tumor size on imaging (cm) 2.9±0.9 2.9±1.3   0.6682
Planned surgery   0.6266
　PD/PPPD 79 (76.0) 60 (69.8)
　DPS 23 (22.1) 24 (27.9)
　TP 2 (1.9) 2 (2.3)
Death (event) 22 (21.2) 12 (14.0)   0.1975
CA, carbohydrate antigen; neo-Tx, neoadjuvant treatment; PD, pancreaticoduodenectomy; PPPD, pylorus-preserving PD; DPS,
distal pancreatosplenectomy; TP, total pancreatectomy; Categorical and continuous variables were analyzed via Chi-square test or
Fisher’s exact test and student’s t-test, respectively.
 
Figure 3  Correlation of  actual  patients’  survival  according to
calculated probability of 1-year disease-specific survival (internal
validation). Low-risk group comprised patients with nomogram-
based calculated 1-year  disease-specific  survival  probability  of
<33.3%; intermediate-risk group, 33.3%−66.6%; and high-risk
group,  >66.6%. The survival  rates  were significantly  different
among the three groups (P<0.001).
110 Hwang et al. Nomogram for pancreatic cancer survival
© Chinese Journal of Cancer Research. All rights reserved. www.cjcrcn.org Chin J Cancer Res 2020;32(1):105-114
81.3%).  In  addition,  Choi  et  al.  (19)  conducted  a
prospective randomized controlled trial on the oncologic
benefits of neoadjuvant treatment in borderline resectable
pancreatic cancer and showed that neoadjuvant treatment
provided oncologic benefit over upfront surgery in patients
with borderline resectable pancreatic cancer. Even in the
metastatic  setting,  FOLFIRINOX  and  nab-paclitaxel-
gemcitabine (20,21) have shown a survival advantage over
previously standard gemcitabine monotherapy; thus, they
have become the standard treatment option in patients with
good performance status. Based on these clinical evidences,
neoadjuvant treatment is expected to be actively used in
managing pancreatic cancer.
Deciding  on  the  necessity  of  radical  pancreatectomy
following  neoadjuvant  for  pancreatic  cancer  can  be
complicated. Most patients who underwent neoadjuvant
treatment have borderline resectable and locally advanced
pancreatic cancer and usually require combined vascular
resection with extensive  surgical  dissection for  margin-
negative  resection.  Several  studies  have  reported  that
extended  radical  pancreatectomy  is  associated  with
increased  morbidity  and  mortality  (10,12).  In  addition,
except for resectable pancreatic cancer, other tumors are
biologically aggressive. Thus, patients are at high risk of
early recurrence and early cancer-related mortality despite
successful  curative  surgical  resection.  Therefore,  the
patients and their families should be well-informed of these
risks  before  surgery.  Moreover,  the  balance  between
potential risk and oncologic benefit should be considered in
deciding the need for surgery. However, many researches
on survival analysis in patients with pancreatic cancer who
underwent surgery following neoadjuvant treatment are
based  on  pathological  examinations  after  surgical
intervention,  such  as  tumor  grade  (22),  pathological
complete response (23), lymph node status (24), perineural
invasion  (25),  and  margin-status  (6).  The  response  of
neoadjuvant chemotherapy is thought to be an important
prognostic factor in pancreatic cancer with neoadjuvant
treatment (23). However, in our clinical practice, it is true
that response to neoadjuvant treatment cannot be always
measured objectively  due  to  inflammatory  changes  and
previous  biliary  stent.  Therefore,  in  order  to  develop
nomogram to be applied in every case of pancreatectomy
following neoadjuvant treatment, we did not include the
response  of  neoadjuvant  chemotherapy,  but  include
preoperative serum CA 19-9 after neoadjuvant treatment.
Methods to preoperatively predict the survival outcome for
these patients are thus important in clinical practice.
In  the  present  study,  only  preoperative  clinical  para-
meters, such as, age, symptom, image-based tumor size at
diagnosis, preoperative serum CA 19-9 after neoadjuvant
treatment,  and  planned  surgery,  were  considered  in
developing  a  nomogram  (internet  calculator;  http://
40.121.207.11:8080/home1.jsp) to predict 1-year survival
outcomes  after  pancreatectomy  following  neoadjuvant
treatment  for  pancreatic  cancer.  In  univariate  analysis,
variables  with  P<0.2  were  age,  body  mass  index  (BMI),
symptom, abdominal pain, CA19-9 (after neo-Tx), CA19-9
(≥34 U/mL,) tumor size, initial resectability, and predicted
surgery. The three parameters (symptom, tumor size, and
planned surgery) were of no significance in multivariate
analysis  but  were  used  in  the  development  of  the
nomogram. The reason for this was to consider the concept
of events per predictor variable (EPV) when constructing
the  nomogram  and  to  include  variables  with  clinical
importance among variables with P<0.2. Although there are
some  variables  that  are  not  significant  when  multiple
logistic regression analysis is performed, the reason why we
built  the prediction model  with these five variables  was
because  we  wanted  to  find  a  model  with  better  overall
model performance than the significance of each variable.
We  selected  this  model  as  the  final  model  because  it
 
Figure 4  Correlation of  actual  patients’  survival  according to
calculated probability of 1-year disease-specific survival (external
validation). Low-risk group: the nomogram-based calculated 1-
year disease-specific survival probability is <33.3%; intermediate-
risk  group:  33.3%−66.6%; and high-risk  group:  >66.6%. The
survival rates were significantly different among the three groups
(P=0.044).
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showed the best performance when modeled using these
five  variables  in  this  data.  Harrell’s  c-index  was  0.684
(SE=0.064)  when  the  nomogram was  created  with  age,
tumor size, and CA19-9 after neoadjuvant treatment with
P<0.05 in univariate analysis and when the nomogram was
created  with  age,  abdominal  pain,  and  CA19-9  after
neoadjuvant treatment, which were selected by the stepwise
selection  method,  the  Harrell’s  c-index  was  0.711
(SE=0.064). Internal validation of the current nomogram
via Harrells’  c-statistics  (0.736) and the calibration plot
demonstrated  its  quite  acceptable  clinical  accuracy.  In
addition, external validation of the clinical availability and
feasibility of the current nomogram in predicting survival
outcome  in  patients  who  underwent  pancreatectomy
following  neoadjuvant  treatment  was  conducted  using
dataset  from 5 international  institutions.  Similar  to  the
primary observation from the development dataset,  the
predicted 1-year disease-specific survival was successfully
correlated  with  actual  survival  outcomes  in  external
validation set,  which is  among the  strong points  of  the
current  nomogram.  However,  when  correlating  actual
disease-specific  survival  and  calculated  1-year  disease-
specific  survival,  the  survival  curves  between  high-risk
group and intermediate-risk group crossed in the external
validation data (Figure 4). We think the statistical power is
a bit lower due to the small number of event cases in the
high-risk  group  in  the  external  data.  Even  though  the
p-value of external validation set increased compared to
development set, considering P-value less than 0.05, the
prediction effect seems to be useful. It was thought to be
meaningful  that  we  performed external  validation  with
multinational data to evaluate generalizability as well  as
internal validation for our prediction model.
However, when we tried the GND goodness-of-fit test
in the survival setting, the number of events was too small
to calculate, therefore, the P-value calculation for accuracy
between predicted value and actual  value seems to be a
limitation  in  this  study.  The  accuracy  and  clinical
application  of  this  nomogram should  be  re-assessed  in
prospective large volume-patient cohorts. To the best of
our knowledge, the preoperatively detectable parameter-
based nomogram to predict 1-year disease-specific survival
is the first to be developed in the era of pancreatectomy
following neoadjuvant treatment for managing pancreatic
cancer. We hope that the present nomogram could provide
crucial information in the decision-making process for the
management  of  pancreatic  patients  who  underwent
neoadjuvant treatment.
There are several limitations in the present study. First,
this  was a  retrospective study with a  limited number of
patients. In addition, initial radiological resectability (26)
and  various  different  neoadjuvant  protocols  were  not
considered  in  the  analysis.  Recently,  preoperative  co-
morbidity index (27,28) and nutritional parameters (29)
have been reported to be independent prognostic factors in
patients  who  underwent  pancreatectomy  following
neoadjuvant  treatment.  The  accuracy  and  clinical
application  of  this  nomogram should  be  re-assessed  in
prospective large volume-patient cohorts. Further, more
accurate  and  reliable  methods  to  calculate  and  predict
survival need to be developed to improve patient-oriented
surgical approach to pancreatic cancer. Particularly, in the
medical field influenced by the 4th Industrial Revolution,
such methods are predicted to be developed via data-based
artificial intelligent algorithms. The continued increase in
available  data  and  emerging  computational  methods
indicate that precision public health is highly likely to be
available in the future (30).
Conclusions
The nomogram to predict 1-year disease-specific survival
for  patients  with pancreatic  cancer  who are  eligible  for
surgery following neoadjuvant treatment showed accuracy
and  clinical  feasibility  for  decision-making  in  the
management of pancreatic cancer.
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